AURORA, ONTARIO--(Marketwired - December 18, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the "Meeting") was held today as scheduled.
Shareholders approved the election of Yvon Bastien, Slawomir Majewski, Marek Orlowski, Sven Rohmann, Robert A. Verhagen, Stacy L. Wills and Slawomir Ludwikowski and as directors at the Meeting. Based on proxies received prior to the Meeting, more than 99% of the shares represented by proxy at the Meeting were voted "for" each of Messrs. Bastien, Majewski, Orlowski, Rohmann, Verhagen and Wills. However, in the case of Mr. Ludwikowski a majority of the votes represented by proxy at the Meeting were withheld from voting and, in accordance with Helix's majority voting policy, Mr. Ludwikowski is required to submit his resignation to the board of directors for its consideration.
In addition, BDO Canada LLP, Chartered Accountants, were appointed as auditors. Shareholders also approved a resolution re-approving the 2010 Equity Compensation Plan and the granting by Helix of options, rights and other entitlements under the 2010 Equity Compensation Plan until December 18, 2016, which is three years from the date of the Meeting.
At a board meeting held after the Meeting, Mr. Verhagen was appointed as President and Chief Executive Officer and Frank Michalargias was appointed as Chief Financial Officer. Pending the selection of a new Chair of the board of directors to replace the former Chair who resigned shortly before the Meeting, Mr. Verhagen was appointed Interim Chair of the board of directors for a term not to exceed 6 months. Following the Meeting Mr. Verhagen said, "given the strong skill sets brought to the board by the directors elected during today's meeting, the board wanted the opportunity to assess the merits of each member before a permanent Chair was chosen. This temporary measure will provide time to allow the board to make the best choice for long term stability".
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. Helix is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".